Paper Details

  1. Home
  2. Paper Details

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.

Author: AballéaSamuel, ChappleChris, HakimiZalmai, KelleherCon, MamanKhaled, NazirJameel, SiddiquiEmad, ZurRichard

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This network meta-analysis compared the efficacy and tolerability of mirabegron 50 mg to antimuscarinic therapies for overactive bladder (OAB). Mirabegron 50 mg was significantly more efficacious than placebo and comparable to most active treatments, with significantly fewer anticholinergic side effects. However, solifenacin 10 mg monotherapy and solifenacin 5 mg plus mirabegron 25 or 50 mg in combination were more efficacious for some outcomes.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. OBJECTIVE: To assess efficacy and tolerability of mirabegron 50mg versus antimuscarinic monotherapie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2018.03.020

データ提供：米国国立医学図書館（NLM）

Overactive Bladder: Finding Relief in the Desert of Urinary Urgency

The field of [urology] is constantly seeking better treatment options for [overactive bladder (OAB)], a condition that can significantly impact quality of life. This study explores the efficacy and tolerability of [mirabegron], a [beta-3 adrenergic receptor agonist], compared to [antimuscarinic monotherapy] and [combination therapies] in managing [OAB]. The research involved a [systematic review and network meta-analysis] of [randomized controlled trials] to assess the effectiveness of [mirabegron] against a range of [OAB treatments]. The study aimed to determine if [mirabegron] offered advantages in terms of both efficacy and tolerability.

Mirabegron: A Potential Oasis in the Desert of OAB

The study found that [mirabegron 50mg] was significantly more effective than [placebo] in reducing [micturition frequency], [urgency urinary incontinence], and improving [dry rate] in patients with [OAB]. The study also indicated that [mirabegron 50mg] was comparable in efficacy to most [active treatments] and was better tolerated than most [active comparators] in terms of [dry mouth], [constipation], and [urinary retention]. This suggests that [mirabegron] might be a valuable alternative for patients seeking relief from [OAB] symptoms.

Mirabegron: A New Approach to Bladder Control

This study highlights the potential of [mirabegron] as a well-tolerated and effective treatment for [OAB]. The research suggests that [mirabegron] might offer a promising alternative for patients who experience side effects from [antimuscarinic therapy]. As a researcher, I am always fascinated by the complex interplay between our bodies and medications. The field of [urology] is a vast desert, and we are always on the lookout for new ways to improve patient care. The search for effective treatments is an ongoing journey.

Dr.Camel's Conclusion

Mirabegron 50mg demonstrated comparable efficacy to a range of antimuscarinics for treating overactive bladder, with the benefit of significantly fewer bothersome anticholinergic side effects. This study provides further evidence supporting the use of mirabegron as a viable treatment option for patients with OAB.

Date :
  1. Date Completed 2019-05-20
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29699858

DOI: Digital Object Identifier

10.1016/j.eururo.2018.03.020

Related Literature

Article Analysis
・Side Effects of solifenacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.